Research programme: RNA interference-based therapeutics - Alnylam/Merck

Drug Profile

Research programme: RNA interference-based therapeutics - Alnylam/Merck

Alternative Names: RNAis - Alnylam/Merck

Latest Information Update: 27 Sep 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alnylam Pharmaceuticals; Merck & Co
  • Class
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Spinal cord injuries; Unspecified

Most Recent Events

  • 27 Sep 2007 Discontinued - Preclinical for Spinal cord injuries in USA (unspecified route)
  • 27 Sep 2007 Discontinued - Preclinical for Undefined indication in USA (unspecified route)
  • 20 Sep 2007 Alnylam Pharmaceuticals and Merck & Co have mutually agreed to terminate their research collaboration
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top